dextroamphetamine sulfate

Also found in: Dictionary, Encyclopedia.

dextroamphetamine sulfate

Dexedrine Spansule, DextroStat

Pharmacologic class: Amphetamine

Therapeutic class: Sympathomimetic amine, CNS stimulant

Controlled substance schedule II

Pregnancy risk category C

FDA Box Warning

• Drug has high abuse potential. Prolonged use may lead to drug dependence. Stay alert for possibility of patient obtaining drug for nontherapeutic use or distribution. Drug should be prescribed sparingly.

• Misuse may cause sudden death and serious cardiovascular events.


Produces CNS and respiratory stimulation by promoting release of norepinephrine from nerve terminals


Capsules (sustained-release): 5 mg, 10 mg, 15 mg

Oral solution: 5 mg/ml

Tablets: 5 mg, 10 mg

Indications and dosages

Attention deficit hyperactivity disorder

Adults: 5 to 60 mg P.O. daily in divided doses until optimal response is obtained

Children ages 6 and older: 5 mg (capsules, oral solution, or tablets) P.O. once or twice daily, increased by 5 mg at weekly intervals until optimal response is obtained

Children ages 3 to 5: 2.5 mg (oral solution) P.O. daily, increased by 2.5 mg at weekly intervals until optimal response is obtained


Adults: 5 to 60 mg P.O. daily as a single dose or in divided doses

Children ages 12 and older: 10 mg P.O. daily, increased by 10 mg at weekly intervals until desired response occurs or adult dosage is reached

Children ages 6 to 11: 5 mg P.O. daily, increased by 5 mg at weekly intervals until desired response occurs or adult dosage is reached


• Hypersensitivity to drug or tartrazine
• Glaucoma
• Psychotic disorders, agitated states
• Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension
• Hyperthyroidism
• MAO inhibitor use within past 14 days
• Pregnancy or breastfeeding


Use cautiously in:
• cardiovascular disease, hypertension, diabetes mellitus
• history of substance abuse
• elderly patients.


• Make sure patient swallows sustained-release capsules whole without chewing or crushing.
• Before starting therapy, perform complete cardiac evaluation, including ECG and echocardiogram.
• Give last daily dose at least 6 hours before patient's bedtime.

Don't give within 14 days of MAO inhibitor, because potentially fatal reaction may occur.

Adverse reactions

CNS: hyperactivity, insomnia, restlessness, tremor, depression, dizziness, headache, irritability

CV: palpitations, tachycardia, hypertension, hypotension, arrhythmias

GI: nausea, vomiting, constipation, diarrhea, abdominal cramps, dry mouth

GU: erectile dysfunction, increased libido

Skin: urticaria

Other: metallic taste, decreased appetite, physical or psychological drug dependence


Drug-drug.Acetazolamide, sodium bicarbonate: urine alkalization, leading to increased dextroamphetamine effects

Adrenergic blockers: additive effects

Ammonium chloride, ascorbic acid (large doses): urine acidification, leading to decreased dextroamphetamine effects

Beta-adrenergic blockers, tricyclic antidepressants: increased risk of adverse cardiovascular effects

Guanethidine: reversal of hypotensive effect

MAO inhibitors: hypertensive crisis

Phenothiazines: decreased dextroamphetamine effects

Selective serotonin reuptake inhibitors: increased risk of serotonin syndrome

Drug-diagnostic tests.Plasma corticosteroids: increased levels

Drug-food.Caffeine: increased stimulant effect

Drug-herbs.Caffeine-containing herbs, ephedra (ma huang): increased stimulant effect

Patient monitoring

• Interrupt therapy or reduce dosage periodically to assess drug efficacy in patients with behavior disorders.
• Monitor patient for new or worsening aggressive behavior.
• Monitor blood and urine glucose levels carefully in diabetic patient. Drug may alter regular insulin requirements.

Patient teaching

• Tell patient to swallow sustained-release capsules whole with liquid without chewing or crushing.
• Advise patient to take drug early in day to avoid insomnia.

Instruct patient to immediately notify prescriber if chest pain, irregular pulse, or worsening aggressive behavior occurs.
• Instruct patient to avoid driving and other hazardous activities until he knows how drug affects him.
• Caution patient not to stop therapy abruptly but to taper dosage gradually.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

dextroamphetamine sulfate

a central nervous system stimulant.
indications It is prescribed in the treatment of narcolepsy, hyperkinetic disorders, and attention deficit disorder in children and as an anorexiant in treating exogenous obesity.
contraindications Cardiovascular disease, glaucoma, hypertension, hyperthyroidism, agitation, history of drug abuse, concomitant administration of a monoamine oxidase inhibitor within 14 days, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse reactions are manifestations of central nervous system excitation, increased blood pressure, arrhythmias and other cardiovascular effects, nausea, anorexia, and drug dependence.

dex·tro·am·phet·a·mine sul·fate

(deks'trō-am-fet'ă-mēn sul'fāt)
Agent similar in action to racemic amphetamine sulfate, but more stimulating to the central nervous system; sympathomimetic and appetite depressant.
Synonym(s): dextroamphetamine sulphate.

dex·tro·am·phet·a·mine sul·fate

(deks'trō-am-fet'ă-mēn sul'fāt)
A sympathomimetic and appetite depressant.

dextroamphetamine sulfate

n brand names: Dexedrine, Oxydess II;
drug class: amphetamine, Controlled Substance Schedule II;
action: increases release of norepinephrine and dopamine in the cerebral cortex to the reticular activating system;
uses: narcolepsy, attention deficit disorder with hyperactivity.
dextromethorphan hydrobromide
(dek´strōməthor´fan hī´drōbrō´mīd),
n brand names: Benylin DM, Robitussin Pediatric, Vicks Formula 44;
drug class: antitussive, nonnarcotic;
action: depresses cough center in medulla;
use: nonproductive cough.
References in periodicals archive ?
Dextroamphetamine Sulfate Tablets, 10 mg: Lots: 73934, 75892, 77945, 81137, 86320 with expiration dates ranging from 6/2009 to 5/2011
The 10 mg Dextroamphetamine Sulfate Tablet is a round, flat-face, bevel edge, orange mottled tablet debossed "ETHEX" and "312" on one side and double- scored on the other side.
If someone were to take a higher than expected dose of Dextroamphetamine Sulfate, then the risk of adverse effects known to be associated with the drug such as tachycardia, hypertension, tremors, decreased appetite, headache, insomnia, dizziness, blurred vision, stomach upset, and dry mouth may be increased.
No report of any oversized Dextroamphetamine Sulfate tablets has been received by ETHEX from any wholesaler, retailer, consumer or caregiver, and ETHEX has not received any report of unexpected side effects or injury related to this product.
Please be aware that there are multiple companies in the United States producing and marketing generic versions of Dextroamphetamine Sulfate 5 mg tablets and consumers and their caregivers are encouraged to check their prescriptions to determine the source of their tablets.
Dextroamphetamine Sulfate Tablets are indicated for the treatment of Attention Deficit Disorder with Hyperactivity, as an integral part of a total treatment program which typically includes other remedial measures for a stabilizing effect in pediatric patients.
of Princeton, New Jersey, a wholly owned subsidiary of Ranbaxy Laboratories, LLC, in an alliance with CorePharma LLC of Middlesex, New Jersey, announced today that they have received FDA approval to manufacture and market the fixed combination of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets in 5mg, 10mg, 20mg and 30mg dosage forms.
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, in combination, are indicated for the treatment of Attention Deficit Disorder (ADHD), most commonly diagnosed as a childhood disorder.
Food & Drug Administration for Dextroamphetamine Sulfate Tablets, USP 5 mg and 10 mg the generic equivalent of Shire Richwood Inc.